CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：18

作者：

Capi, Matilde ^{[1
]}

De Angelis, Valerio ^{[2
]}

De Bernardini, Donatella ^{[1
]}

De Luca, Ottavia ^{[3
]}

Cipolla, Fabiola ^{[2
]}

Lionetto, Luana ^{[1
]}

Simmaco, Maurizio ^{[1
,3
,4
]}

Martelletti, Paolo ^{[2
]}

机构：

[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy

[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy

[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy

[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期

关键词：

migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;

D O I：

10.3390/jcm10071429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.

引用

页数：17

共 47 条

[1] Current and emerging evidence-based treatment options in chronic migraine: a narrative review [J].

Agostoni, Elio Clemente ;

Barbanti, Piero ;

Calabresi, Paolo ;

Colombo, Bruno ;

Cortelli, Pietro ;

Frediani, Fabio ;

Geppetti, Pietrangelo ;

Grazzi, Licia ;

Leone, Massimo ;

Martelletti, Paolo ;

Pini, Luigi Alberto ;

Prudenzano, Maria Pia ;

Sarchielli, Paola ;

Tedeschi, Gioacchino ;

Russo, Antonio .

JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01)

[2]

[Anonymous], Efficacy and Safety of Seralutinib in Adult Subjects with PAH (PROSERA)

[3]

[Anonymous], NCT03461757

[4]

[Anonymous], An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease - Full Text View - ClinicalTrials.gov

[5]

[Anonymous], A Dose-finding Study of MK-8628 in Participants With Recurrent Glioblastoma Multiforme MK-8628-002

[6]

[Anonymous], Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

[7]

[Anonymous], NCT03266588

[8]

[Anonymous], DOSE RANGING STUDY R

[9]

[Anonymous], NCT02439320

[10]

[Anonymous], NCT03872453

← 1 2 3 4 5 →